Search results for "Antipsychotic"

showing 10 items of 189 documents

Prediction of acute clinical response following a first episode of non affective psychosis: results of a cohort of 375 patients from the Spanish PAFI…

2013

Abstract Objective Predicting response to antipsychotic treatment might optimize treatment strategies in early phases of schizophrenia. We aimed to investigate sociodemographic, premorbid and clinical predictors of response to antipsychotic treatment after a first episode of non-affective psychosis. Method 375 (216 males) patients with a diagnosis of non affective psychosis entered the study. The main outcome measure was clinical response at 6 weeks and variables at baseline were evaluated as predictors of response. ANOVA for continuous and chi-square for categorical data were used to compare responders and non-responders. Multivariate logistic regression was used to establish a prediction …

AdultMalePsychosismedicine.medical_specialtyAdolescentLogistic regressionCohort StudiesYoung AdultPredictive Value of TestsOutcome Assessment Health CaremedicineHumansFamily historyPsychiatryBiological PsychiatryRetrospective StudiesPharmacologyFirst episodePsychiatric Status Rating ScalesAnalysis of VarianceChi-Square DistributionMiddle Agedmedicine.diseaseLogistic ModelsPsychotic DisordersSchizophreniaSpainCohortdupFemalePsychologyDiagnosis of schizophreniaAntipsychotic AgentsProgress in neuro-psychopharmacologybiological psychiatry
researchProduct

Impact of NTRK2, DRD2 and ACE polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis.

2018

Background: Hyperprolactinemia is a common side-effect of antipsychotics (APs), which may trigger serious secondary problems and compromise the adherence to treatment which is crucial for prognosis, especially in patients presenting with a first-episode of psychosis (FEP). Aims: We evaluated, in some cases for the first time, the effect of polymorphisms in multiple candidate genes on serum prolactin (PRL) levels in an AP-treated FEP cohort recruited in the multicenter PEPs study (Phenotype − genotype and environmental interaction; Application of a predictive model in first psychotic episodes). Methods: PRL concentration was measured in serum from 222 patients. A total of 167 polymorphisms w…

AdultMalePsychosismedicine.medical_specialtyCandidate geneSerotoninSide effectAdolescentmedicine.medical_treatmentDopaminePeptidyl-Dipeptidase A03 medical and health sciencesYoung Adult0302 clinical medicineDopaminePolymorphism (computer science)Internal medicinemedicineHumansReceptor trkBPharmacology (medical)AntipsychoticPharmacologyMembrane GlycoproteinsPolymorphism Geneticbusiness.industryReceptors Dopamine D2medicine.diseaseProlactin030227 psychiatryProlactinHyperprolactinemiaPsychiatry and Mental healthEndocrinologyPsychotic DisordersCohortFemalebusiness030217 neurology & neurosurgerymedicine.drugAntipsychotic AgentsJournal of psychopharmacology (Oxford, England)
researchProduct

Seroquel (ICI 204 636), a putative "atypical" antipsychotic, in schizophrenia with positive symptomatology: results of an open clinical trial and cha…

1995

Preclinical data indicated that seroquel (ICI 204 636), a dibenzothiazepine with 5-HT2 and D2-like receptor antagonistic properties, might be an effective antipsychotic agent, causing fewer extrapyramidal side effects than typical neuroleptics. In the present study, 12 patients suffering from schizophrenia or schizophreniform disorder with predominantly positive symptomatology were treated in an open clinical trial for 4 weeks with seroquel at a maximum dosage of 750 mg/day. The drug was generally well tolerated, and virtually no adverse extrapyramidal side effects such as acute dystonia, parkinsonism or akathisia were observed. Total scores for BPRS (item score 0–6; baseline: 42.0±2.3; mea…

AdultMalePsychosismedicine.medical_specialtyDibenzothiazepinesTime Factorsmedicine.drug_classmedicine.medical_treatmentAtypical antipsychoticThyrotropinAkathisiaGastroenterologyQuetiapine FumarateAntipsychotic AgentInternal medicinemedicineHumansSchizophreniform disorderAntipsychoticAgedPharmacologyPsychiatric Status Rating ScalesParkinsonismElectroencephalographyMiddle Agedmedicine.diseaseProlactinTreatment OutcomeSchizophreniaAnesthesiaSchizophreniaFemaleSchizophrenic Psychologymedicine.symptomPsychologyAntipsychotic AgentsPsychopharmacology
researchProduct

The relevance of cognitive, clinical and premorbid variables in predicting functional outcome for individuals with first-episode psychosis: A 3 year …

2013

Real-world functional deficits are common and persistent in individuals with psychosis. Cognitive deficits have been shown to compromise functioning. We aimed to study the predictive values of premorbid, sociodemographic, and baseline clinical and neurocognitive factors on long-term functional outcome for individuals with first episode non-affective psychosis. We failed to demonstrate a significant relationship between cognitive deficits at baseline and functional disability at 3 year follow-up. Diagnosis of schizophrenia (OR=2.457, p=0.011), shorter education (OR=1.177, p=0.005) and poor premorbid social adjustment (OR=1.628, p=0.013) emerged as the strongest predictors for the 114 subject…

AdultMalePsychosismedicine.medical_specialtyLongitudinal studyAdolescentNeuropsychological TestsOutcome (game theory)Disability EvaluationYoung AdultPredictive Value of TestsmedicineHumansLongitudinal StudiesPsychiatryBiological PsychiatryRetrospective StudiesFirst episodeCognitionMiddle AgedPrognosismedicine.diseasePsychiatry and Mental healthLogistic ModelsPsychotic DisordersSocioeconomic FactorsSchizophreniaFemaleCognition DisordersPsychologyNeurocognitiveAntipsychotic AgentsDiagnosis of schizophreniaPsychiatry Research
researchProduct

Duration of active psychosis and functional outcomes in first-episode non-affective psychosis.

2018

AbstractBackground:The duration of untreated psychosis (DUP) has been associated with negative outcomes in psychosis; however, few studies have focused on the duration of active psychotic symptoms after commencing treatment (DAT). In this study, we aimed to evaluate the effect of DUP and DAT on functional long-term outcomes (3 years) in patients with early psychosis.Methods:We evaluated the Scale for the Assessment of Positive Symptoms (SAPS) at frequent intervals for 3 years after presentation to determine the DAT for 307 individuals with first-episode psychosis together with DUP and clinical variables. The functional outcomes were assessed using the Disability Assessment Scale (DAS) at th…

AdultMalePsychosismedicine.medical_specialtyTime FactorsLogistic regressionCohort Studies03 medical and health sciencesDisability Evaluation0302 clinical medicineActivities of Daily LivingmedicineHumansProspective StudiesPsychiatryProspective cohort studyFirst episodePsychiatric Status Rating ScalesReceiver operating characteristicbusiness.industrymedicine.disease030227 psychiatryPsychiatry and Mental healthTreatment OutcomePsychotic DisordersSchizophreniaNon affective psychosisdupSchizophreniaFemaleSchizophrenic PsychologybusinessSocial Adjustment030217 neurology & neurosurgeryAntipsychotic AgentsEuropean psychiatry : the journal of the Association of European Psychiatrists
researchProduct

Experience of Psychotropic Medication -An Interview Study of Persons with Psychosis.

2016

Psychotropic drugs, particularly antipsychotic types, are a cornerstone of the treatment of people with psychosis. Despite numerous studies showing that drug treatment with psychotropic drugs initially alleviates psychiatric symptoms, the proportion of people with mental health problems and symptoms that do not follow doctors' prescriptions, thus exhibiting so-called non-adherence, is considerable. Non-adherence is predominantly seen as a clinical feature and as a patient characteristic that is especially due to patients' poor understanding that they are ill. There is also a widespread notion that non-adherence is of great disadvantage to the patient. This article is based on interviews wit…

AdultMalePsychosismedicine.medical_specialtymedicine.medical_treatmentMedication adherencePsychotropic medicationMedication Adherence03 medical and health sciencesDrug treatmentYoung Adult0302 clinical medicinemedicineHumans030212 general & internal medicineYoung adultPatient participationAntipsychoticPsychiatryAgedPsychotropic Drugsbusiness.industryPatient PreferenceMiddle Agedmedicine.disease030227 psychiatryPsychotic DisordersInterview studyFemalePshychiatric Mental HealthPatient ParticipationbusinessClinical psychologyIssues in mental health nursing
researchProduct

The applicability of SRTM in [18F]fallypride PET investigations: Impact of scan durations

2011

The high-affinity radioligand [18F]fallypride (FP) is frequently used for quantification of striatal/extrastriatal D2/3 receptors and the receptor occupancies of antipsychotics (APs). Its 110 minutes half-life allows long scan durations. However, the optimum scan duration is a matter of debate. This investigation focuses on scan-duration-related effects on simplified reference tissue model (SRTM) results and the time point of transient equilibrium in a large sample of dynamic FP positron emission tomography (PET) scans. Fifty drug-free and 50 AP-treated subjects underwent FP-PET scans (180 minutes scan duration). The binding potential ( BPND) of the putamen, thalamus, and temporal cortex w…

AdultMalePyrrolidinesTime FactorsMaterials scienceAdolescentShuttle Radar Topography MissionRadioligand AssayYoung AdultRadioligandmedicineHumansTemporal cortexTransient equilibriummedicine.diagnostic_testReceptors Dopamine D2business.industryMental DisordersPutamenReceptors Dopamine D3Binding potentialMiddle AgedCorpus StriatumNeurologyFallypridePositron emission tomographyPositron-Emission TomographyBenzamidesFemaleOriginal ArticleNeurology (clinical)Cardiology and Cardiovascular MedicineNuclear medicinebusinessAntipsychotic AgentsJournal of Cerebral Blood Flow & Metabolism
researchProduct

Melperone is an Inhibitor of the CYP2D6 Catalyzed O-demethylation of Venlafaxine

2003

INTRODUCTION Melperone, a butyrophenone neuroleptic, is frequently used for its sleep-inducing properties. Despite its common use for more than 30 years, it is not yet characterized regarding its effects on cytochrome P450 s (CYPs). In an open pilot study, effects of melperone on the steady-state blood levels of venlafaxine, a recently introduced serotonin- and noradrenaline reuptake inhibiting antidepressant, were assessed. METHODS The dose-corrected serum concentrations of venlafaxine and O-desmethylvenlafaxine were analyzed retrospectively in a therapeutic drug-monitoring (TDM) database comprising 94 patients. In addition, three patients received venlafaxine and melperone concomitantly a…

AdultMaleSleep Wake Disordersmedicine.medical_specialtyMelperoneVenlafaxine HydrochlorideVenlafaxinePharmacologyMethylationPharmacokineticsOral administrationCytochrome P-450 CYP2D6 InhibitorsInternal medicineDextrorphanmedicineHumansDrug InteractionsPharmacology (medical)AgedRetrospective StudiesChemistryVenlafaxine HydrochlorideGeneral MedicineDextromethorphanMiddle AgedCyclohexanolsButyrophenonesPsychiatry and Mental healthEndocrinologyCytochrome P-450 CYP2D6Drug Therapy CombinationFemaleDrug MonitoringReuptake inhibitorSelective Serotonin Reuptake InhibitorsAntipsychotic Agentsmedicine.drugPharmacopsychiatry
researchProduct

Time Course of 5-HT2A Receptor Occupancy in the Human Brain after a Single Oral Dose of the Putative Antipsychotic Drug MDL 100,907 Measured by Posit…

1997

MDL 100,907 is a potent and selective antagonist of 5-HT2A serotonin receptors. Animals studies suggest that MDL 100,907 may behave as an atypical antipsychotic drug. Positron emission tomograph (PET) using [11C]NMSP as the radiotracer was used to define the time course of 5-HT2 receptor occupancy in the human frontal cerebral cortex after a single oral dose of MDL 100,907 (10 or 20 mg) in nine healthy subjects. After the baseline scan each subject was studied three times post dosing at various time points. 5-HT2 occupancies were in the range of 70 and 90% after each dose. While the occupancy remains in this range over 24 hours after 20 mg MDL 100,907, it decreases by about 20% at 24 hours …

AdultMaleTime Factorsmedicine.drug_classAtypical antipsychoticPharmacologyPiperidinesOral administrationmedicineHumansReceptor Serotonin 5-HT2ACarbon RadioisotopesPositron emissionDosing5-HT receptorPharmacologymedicine.diagnostic_testbusiness.industry5-HT2 receptorBrainHuman brainFluorobenzenesPsychiatry and Mental healthmedicine.anatomical_structureSpiperonePositron emission tomographyReceptors SerotoninFemaleSerotonin AntagonistsbusinessAntipsychotic AgentsTomography Emission-ComputedNeuropsychopharmacology
researchProduct

Response trajectories in "real-world" naturalistically treated schizophrenia patients.

2011

Abstract Background To date, research has identified distinct antipsychotic response trajectories yet focussing on data from randomized-controlled trials (RCTs). Therefore, the heterogeneity of response in “real-world” schizophrenia patients is still unknown. Methods Antipsychotic response was evaluated in 399 patients suffering from a schizophrenia spectrum disorder within a naturalistic multicenter study of the Competence Network on Schizophrenia using latent class regression. Baseline and illness-related variables were compared between the different trajectory classes as well as currently proposed outcome definitions (early improvement, response, remission) using univariate tests. In ord…

AdultMaleTime Factorsmedicine.medical_treatmentMedizin03 medical and health sciencesYoung Adult0302 clinical medicinemedicineHumansYoung adultAntipsychoticBiological PsychiatryRetrospective StudiesPsychiatric Status Rating ScalesUnivariateRetrospective cohort studyRegression analysisMiddle AgedResponse to treatment030227 psychiatryDiagnostic and Statistical Manual of Mental DisordersHospitalizationPsychiatry and Mental healthTreatment OutcomeMulticenter studySchizophreniaRegression AnalysisFemaleSchizophrenic PsychologyPsychology030217 neurology & neurosurgeryClinical psychologySchizophrenia spectrumAntipsychotic AgentsFollow-Up StudiesSchizophrenia research
researchProduct